GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Consumer Nigeria PLC (NSA:GLAXOSMITH) » Definitions » Cash And Cash Equivalents

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Cash And Cash Equivalents : ₦21,203 Mil (As of Jun. 2023)


View and export this data going back to 2001. Start your Free Trial

What is GlaxoSmithKline Consumer Nigeria Cash And Cash Equivalents?

GlaxoSmithKline Consumer Nigeria's quarterly cash and cash equivalents increased from Sep. 2022 (₦16,231.58 Mil) to Dec. 2022 (₦18,000.87 Mil) and increased from Dec. 2022 (₦18,000.87 Mil) to Jun. 2023 (₦21,203.33 Mil).

GlaxoSmithKline Consumer Nigeria's annual cash and cash equivalents declined from Dec. 2020 (₦11,161.77 Mil) to Dec. 2021 (₦10,907.09 Mil) but then increased from Dec. 2021 (₦10,907.09 Mil) to Dec. 2022 (₦18,000.87 Mil).


GlaxoSmithKline Consumer Nigeria Cash And Cash Equivalents Historical Data

The historical data trend for GlaxoSmithKline Consumer Nigeria's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Consumer Nigeria Cash And Cash Equivalents Chart

GlaxoSmithKline Consumer Nigeria Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,388.94 2,210.21 11,161.77 10,907.09 18,000.87

GlaxoSmithKline Consumer Nigeria Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,423.72 10,993.83 16,231.58 18,000.87 21,203.33

GlaxoSmithKline Consumer Nigeria Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


GlaxoSmithKline Consumer Nigeria  (NSA:GLAXOSMITH) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


GlaxoSmithKline Consumer Nigeria Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Consumer Nigeria's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Business Description

Traded in Other Exchanges
N/A
Address
No. 1, Industrial Avenue, Ilupeju, P.M.B. 21218, Ikeja, GSK House, Lagos, NGA
GlaxoSmithKline Consumer Nigeria PLC is a healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. The company has two reportable segments, the Consumer Healthcare segment consisting of oral care, over-the-counter (OTC) medicines, and nutritional healthcare; and the Pharmaceuticals segment consisting of vaccines and prescription drugs. The company's product line includes panadol, Andrews liver salt, Macleans, ampiclox, Sensodyne, and others. The generates maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Headlines

No Headlines